title: Bioactive properties and clinical safety of a novel milk protein peptide.
abstract: BACKGROUND
  Milk protein fractions and peptides have been shown to have bioactive properties. This preliminary study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP).
  
  
  RESULTS
  A novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC50 of 9.85 μM, 7.7 μM, and 6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C. elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All clinical blood markers remained within normal levels and no clinically significant side effects were reported. There was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life assessment of role of physical function.
  
  
  CONCLUSIONS
  These data in combination with the observed in vitro anti-cancer properties warrant further clinical studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life and clinical outcomes in cancer patients.
  
  
  BACKGROUND
  NCT01412658.
authors.affiliation: Exercise and Sport Nutrition Laboratory, Department of Health & Kinesiology, Texas A&M University College Station, TX 77843-4243, USA. rkreider@hlkn.tamu.edu
authors.forename: Richard B
authors.initials: RB
authors.lastname: Kreider
authors.forename: Mike
authors.initials: M
authors.lastname: Iosia
authors.forename: Matt
authors.initials: M
authors.lastname: Cooke
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Hudson
authors.forename: Chris
authors.initials: C
authors.lastname: Rasmussen
authors.forename: Helen
authors.initials: H
authors.lastname: Chen
authors.forename: Olof
authors.initials: O
authors.lastname: Mollstedt
authors.forename: Men-Hwei
authors.initials: MH
authors.lastname: Tsai
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D017173:Caenorhabditis elegans / Q000187:drug effects / Q000254:growth & development; D002417:Cattle; D004311:Double-Blind Method; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D019073:HT29 Cells / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D008875:Middle Aged; D008894:Milk Proteins / Q000494:pharmacology* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011972:Receptor, Insulin / Q000037:antagonists & inhibitors; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D008894:Milk Proteins; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D011972:Receptor, Insulin; D040301:Vascular Endothelial Growth Factor Receptor-2